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Coronary Artery Calcification (CAC) and Post-Trial Cardiovascular
Events and Mortality Within the Women’s Health Initiative (WHI)
Estrogen-Alone Trial
Indu G. Poornima, MD;* Rachel H. Mackey, PhD, MPH;* Matthew A. Allison, MD, MPH; JoAnn E. Manson, MD, Dr PH; J. Jeffrey Carr, MD,
MSc; Michael J. LaMonte, PhD, MPH; Yuefang Chang, PhD; Lewis H. Kuller, MD, Dr PH; for the WHI and WHI-CAC Study Investigators†
Background-—Among women aged 50 to 59 years at baseline in the Women’s Health Initiative (WHI) Estrogen-Alone (E-Alone) trial,
randomization to conjugated equine estrogen-alone versus placebo was associated with lower risk of myocardial infarction and
mortality, and, in an ancillary study, the WHI-CACS (WHI Coronary Artery Calcification Study) with lower CAC, measured by cardiac
computed tomography 8.7 years after baseline randomization. We hypothesized that higher CAC would be related to post-trial
coronary heart disease (CHD), cardiovascular disease (CVD), and total mortality, independent of baseline randomization or risk
factors.
Methods and Results-—WHI-CACS participants (n=1020) were followed 8 years from computed tomography scan in 2005 (mean
age=64.4) through 2013 for incident CHD (myocardial infarction and fatal CHD, n=17), CVD (n=69), and total mortality (n=55).
Incident CHD and CVD analyses excluded women with CVD before scan (n=89). Women with CAC=0 (n=54%) had very low age-
adjusted rates/1000 person-years of CHD (0.91), CVD (5.56), and mortality (3.45). In comparison, rates were 2-fold higher for
women with any CAC (>0). Associations were not modified by baseline randomization to conjugated equine estrogen–alone versus
placebo. Adjusted for baseline randomization and risk factors, the hazard ratio (95% confidence interval) for CAC >100 (19%) was
4.06 (2.11, 7.80) for CVD and 2.70 (1.26, 5.79) for mortality.
Conclusions-—Among a subset of postmenopausal women aged 50 to 59 years at baseline in the WHI E-Alone Trial, CAC at mean
age of 64 years was strongly related to incident CHD, CVD, and to total mortality over 8 years, independent of baseline
randomization to conjugated equine estrogen–alone versus placebo or CVD risk factors.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identifier: NCT00000611. ( J Am Heart Assoc. 2017;6:
e006887. DOI: 10.1161/JAHA.117.006887.)
Key Words: cardiovascular disease • coronary artery calcification • hormonal therapy • mortality • women
I n the Women’s Health Initiative (WHI) randomized clinicaltrial of Estrogen-Alone (E-Alone), conducted among hys-
terectomized postmenopausal women aged 50 to 79 years at
baseline, randomization to oral conjugated equine estrogen
alone (CEE-alone) was not associated with reduced risk of
coronary heart disease (CHD).1 However, an a priori subgroup
analysis showed that among younger women (ages 50–59
years at study entry), randomization to CEE-alone was
associated with a lower risk of the composite CHD end point
(myocardial infarction [MI] +CHD death+coronary
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revascularization, hazard ratio [HR]: 0.66, 95% confidence
interval [CI], 0.44–0.97) at the end of the intervention period.2
Similarly, in extended follow-up (13 years postrandomiza-
tion) among women aged 50 to 59 years at baseline,
randomization to CEE-Alone versus placebo was associated
with lower risk of incident MI (HR [95% CI]=0.60 [0.39, 0.91]),
CHD (HR [95% CI]=0.65 [0.44, 0.96]), and total mortality (HR
[95% CI]= 0.78 [0.59, 1.03]).3 The benefit of CEE-alone
(versus placebo) persisted in this 13-year post-trial follow-up,
because of benefit during the intervention period, without
additional reduction in risk during the postintervention
period3,4
An ancillary study, the WHI CACS (Coronary Artery
Calcification Study) was conducted to test the hypothesis
that randomization to CEE-alone reduced CHD in women aged
50 to 59 years at randomization by reducing development
and progression of atherosclerosis, as measured by CAC. CAC
was measured 1.3 years after the end of the trial,
8.7 years after randomization (Figure 1) among a subset
of WHI E-Alone Trial participants aged 50 to 59 years at
baseline. The WHI-CACS reported that women randomized to
CEE-Alone had lower risk of CAC >100 (multivariable-adjusted
odds ratio [OR]=0.69 [95% CI, 0.48, 0.98]) compared with
women randomized to placebo. This association was adjusted
for cardiovascular disease (CVD) risk factors associated with
CAC, including current smoking (OR for CAC >100=4.18,
P=0.001), hypertension (OR=1.67, P=0.01), high cholesterol
(OR=1.89, P=0.03), diabetes mellitus (OR=3.08, P=0.0003),
family history of MI at a premature age (OR=1.60, P=0.04),
and body mass index (BMI) >35 kg/m2 (OR=2.04, P=0.03).5
Therefore, we hypothesized that in WHI-CACS, CAC would
be strongly associated with incident CHD, CVD, and total
mortality during extended follow-up from CAC scan (2005)
through 2013, independent of prior randomization and CVD
risk factors. We further hypothesized that CAC associations
with outcomes would be independent of predictors of CAC,
including baseline randomization to CEE-Alone versus placebo
and CVD risk factors. Finally, we hypothesized that CAC would
substantially explain associations of baseline randomization
and risk factors with post-trial events and mortality. Specif-
ically, our aims were (1) to compare CAC with baseline
randomization and CVD risk factors, as predictors of incident
CHD and CVD and total mortality; and (2) to compare CAC
associations with outcomes for CEE-Alone versus placebo.
Long-term follow-up of the WHI-CACS provides a unique
opportunity to evaluate whether prior randomized estrogen-
alone hormone therapy modifies the relationship between
CAC and subsequent CVD or all-cause mortality.
Methods
This study evaluates incident CHD and CVD events and total
mortality among women who participated in the WHI-CACS,
Figure 1. WHI-CACS study timeline. CAC indicates coronary artery calcium; CACS, Coronary Artery
Calcification study; CT, clinical trial; E-Alone, estrogen-alone; WHI, Women’s Health Initiative.
Clinical Perspective
What Is New?
• Among hysterectomized postmenopausal women aged 50
to 59 years at baseline in the E-Alone Trial (Women’s Health
Initiative Estrogen-Alone Trial), higher coronary artery calci-
fication (CAC) 8 years after baseline was strongly related
to subsequent coronary heart disease, cardiovascular
disease (CVD), and total mortality over 8 years.
• Although baseline CVD risk factors and randomized estro-
gen treatment were previously shown to be related to CAC
measured 8 years later, associations of CAC with incident
outcomes were largely unaffected by prior levels of CVD risk
factors or randomized estrogen treatment.
What Are the Clinical Implications?
• Among postmenopausal women with a mean age of 64
years, coronary heart disease, CVD, and mortality rates are
very low among those with CAC=0, are higher with any CAC
(>0), and very high among those with CAC=400.
• Because prior risk factor exposures are the primary
determinants of CAC, prevention of CVD risk factors early
in pre- or perimenopause could substantially reduce coro-
nary heart disease, CVD, and mortality among post-
menopausal women.
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an ancillary study of WHI E-Alone trial participants who were
aged 50 to 59 years at randomization. For both the WHI
E-Alone trial and the WHI-CACS, institutional review board
approval was obtained at each clinical center and all
participants provided written informed consent.
E-Alone Trial
The design and methods of the WHI E-Alone trial and baseline
participant characteristics have been published.1 Briefly, the
participants were postmenopausal women with prior hys-
terectomy and aged 50 to 79 years at randomization. Women
were randomized to oral CEE (0.625 mg per day, Premarin,
Wyeth Pharmaceuticals) or placebo. The WHI E-Alone trial was
originally scheduled to continue through closeout visits
between October 2004 and March 2005. However, the trial
was stopped 1 year early, because of an increased risk of
stroke and no decreased risk of CHD. On March 1, 2004,
study participants were informed of this decision, their group
assignment, and instructed to discontinue the study
medication.1
At baseline (1995–1998), data were collected on demo-
graphics, medical history, medications, measured height,
weight, and blood pressure.1,6 Lipids and glucose were not
routinely measured in WHI participants. Therefore, as in
previous reports, high cholesterol was defined as physician’s
diagnosis and/or treatment for high cholesterol. Diabetes
mellitus was defined as a physician’s diagnosis that required
oral medication or insulin.1 Hypertension (systemic) was
defined as systolic blood pressure ≥140 mm Hg or diastolic
blood pressure ≥90 mm Hg or use of antihypertensive
therapy. Recreational physical activity was calculated from
self-report based on a structured questionnaire, defined as
expenditure of energy from recreational physical activity
(includes walking, mild, moderate, and strenuous physical
activity) and expenditure of energy was estimated by total
metabolic equivalents per week (kcal/wk per kg), as previ-
ously described in detail.1 Cigarette smoking was categorized
as current, past, or never. In sensitivity analyses, current
smokers were categorized as 1 to 14 cigarettes/d or >15
cigarettes/d, and systolic blood pressure was categorized as
<118, 118 to 130, and >130 mm Hg.
Design of the WHI-CACS Ancillary Study
The WHI E-Alone Trial had 40 clinical sites that randomized
women to CEE-alone or placebo. Of these women, 3310 were
aged 50 to 59 years at baseline, of whom 1637 were
randomized to CEE-alone and 1673 to placebo. The WHI-
CACS was able to include 2271 of these women from 28 of
the WHI clinical sites.5 Exclusion criteria were (1) a request by
the participant for no further clinic visits; (2) weight of
≥300 lb (136 kg) precluding CACS assessment because of
technical restrictions; or (3) loss to follow-up or death since
randomization. Following exclusion for 1 or more of these
reasons (n=529, 23.3%), 1742 women were eligible and were
sent invitational letters. A total of 1079 women (61.9% of the
1742 eligible participants at the 28 clinical centers) provided
written informed consent and underwent cardiac computed
tomography (CT) examinations between May 2005 and
September 2005. The mean time from randomization to
CAC scan was 8.7 years, including mean=7.4 years of the
trial and mean=1.3 years after the intervention stopped
(Figure 1).
CAC Measurement
Noninvasive imaging for coronary artery calcification was
performed with the use of electron-beam or multidetector-row
CT at the 28 participating centers, as previously described.5 A
standardized protocol was used to obtain phantom and test
images.7–9 At a central reading center at Wake Forest
University, the Agatston scores were calculated at a computer
workstation by experienced image analysts using established
criteria, and without knowledge of randomization status.5,8 Of
the 1079 participants with CT scans, 3 women had incom-
plete scans, and 12 women were excluded because of history
of coronary revascularization or presence of stents, leaving
1064 participants in the WHI-CACS.5
Follow-Up for Events
WHI-CACS participants were followed for events according
to WHI E-Alone trial methods.1,10 Cardiovascular outcomes
and deaths were identified by semiannual or annual follow-
up with participants, or family, friends, medical care
providers, obituaries, and the National Death Index. Primary
analyses evaluated events that occurred after the CT scans
(2005) through September 2013, with mean follow-up of
8 years (Figure 1). CHD was defined as first occurrence of
clinical MI, definite silent MI, or death as a result of definite
or possible CHD. Both incident and prevalent CVD were
defined as CHD, stroke, angina, coronary revasculariza-
tion, carotid surgery, peripheral vascular disease, and CVD
death. Events were also classified by whether they were
first CVD event or all CVD events (ie, first and subsequent
events).
After the cardiac CT scan, 44 women had no follow-up for
events other than death (from the National Death Index), and
so were excluded from all analyses of CHD and CVD events,
and from primary mortality analyses. CHD and CVD analyses
also excluded 89 women with CVD before CAC measurement.
Of these, 40 had prevalent CVD at entry to the WHI E-Alone
Trial and 49 had CVD events that occurred between
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randomization and the CT scan. Therefore, primary mortality
analyses included 1020 women (N=1064 minus 44) and
primary CHD and CVD analyses included 931 women
(N=1020 minus 89). Sensitivity analyses evaluated potential
effects of these exclusions on results.
Statistical Analysis
Between-group differences were assessed using t tests,
Wilcoxon, and v2 tests, as appropriate. CAC scores were
skewed, with >50% of participants having CAC=0. Therefore,
CAC scores were categorized as 0, 1 to 100, and >100, or 0,
1 to 10, 11 to 100, 101 to 400, and >400 Agatston units.
Age-adjusted event rates and 95% CIs per 1000 person-years
(PY) were calculated for categories of CAC, CEE-Alone versus
placebo, and risk factors using the direct method with the
entire WHI E-Alone Trial as the standard population. Associ-
ations of CAC categories and risk factors measured at
baseline with events were tested using Cox proportional
hazards regression. Models were adjusted for age, and then
sequentially for randomization status and CVD risk factors.
Specifically, we tested whether higher CAC is independently
associated with incident events and whether associations are
modified by prior randomization to E-Alone or to placebo.
Effect modification, or interaction, was evaluated on the
additive scale by comparing age-adjusted rates for women
previously randomized to E-alone versus placebo (homogene-
ity of effects). Effect modification or interaction was also
evaluated on the relative scale by including a multiplicative
interaction term (E-Alone versus placebo*CAC category) in
Cox regression models, with P<0.05 indicating significant
interaction on the multiplicative scale. The proportional
hazards assumption for CAC categories was tested by
including interaction terms for time 9 CAC categories, and
was met in all models.
Results
Participant Characteristics
For the 1020 women with follow-up data, at the baseline WHI
visit mean age was 55.1 years (range 50–59), mean BMI was
30.6 kg/m2, 11.54% were current smokers, 31.37% had
hypertension, 9.55% had high cholesterol, and 47.94% had a
family history of MI in first-degree relative (Table S1). At the
time of CT scan, 8.7 years after WHI baseline, the mean age
was 64.4 years, and 8.7% had prior CVD. More than half of
the women (n=550, 54%) had CAC=0, 27% (n=273) had
CAC=1 to 100, and 19% (n=197) had CAC >100 (Table S1).
Stratified by prior randomization to CEE-alone (n=517) versus
placebo (n=503), risk factors among the 1020 women with
follow-up data were similar, but CAC was lower among women
previously randomized to CEE-alone (Table S1) as previously
reported for the entire WHI-CACS.5 Sensitivity analyses
showed similar results when restricted to the 931 women
without CVD before scan (not shown). Furthermore, the
distribution of CAC scores in the 44 women without follow-up
visits was similar to the overall population (not shown).
Age-Adjusted Event Rates by CAC Categories
Among the 931 women with no CVD before the scan, 69 first
CVD events, including 2 CVD deaths, occurred during the 8-
year follow-up after scan. Age-adjusted incidence rates of
CVD and coronary revascularization were higher with higher
CAC categories (Figure 2). CHD, angina, and stroke (to a
Figure 2. Age-adjusted CVD rates per 1000 PYs, by CAC categories. Results are among women without
CVD before scan, n=931. Results for CVD and angina are for first events only. Results for CHD, stroke, and
coronary revascularization include first and subsequent events. CAC categories defined as 0, 1 to 100,
>100. Error bars show 95% confidence intervals for rates. CAC indicates coronary artery calcium; CHD,
coronary heart disease; CVD, cardiovascular disease; PYs, person-years.
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lesser extent) showed a similar pattern of higher rates with
higher CAC categories, although confidence intervals were
wide because of the small number of events (Figure 2).
Results were similar for first events and for all (including
subsequent) events (not shown). Similarly, among the 1020
women with follow-up, total mortality, CVD mortality, and non-
CVD mortality were all higher for CAC ≥100 than CAC=0,
despite the small number of events for CVD mortality
(Figure 3). In sensitivity analyses, results for mortality were
similar if women with prior CVD were excluded, or those
without follow-up data other than National Death Index (n=44)
were included (not shown).
Stratified by baseline randomization to CEE-Alone versus
placebo (Table 1), CHD, CVD, and total mortality age-adjusted
rates/1000 PYs were all higher with higher CAC categories,
but were similar for women previously randomized to CEE-
Alone compared with placebo, both within CAC categories and
for the entire group (Table 1). Thus, for all 3 outcomes, there
was no evidence that randomization status modified CAC
associations with absolute risk (age-adjusted rates). Similarly,
there was no evidence of interaction assessed via a
multiplicative interaction term (CEE-alone versus placebo*-
CAC categories) in age-adjusted Cox models (not shown).
Age-Adjusted CHD Rates by CAC and Baseline
Risk Factor Categories
Given the low number of CHD events (n=17) among women
without CVD before scan, we did not calculate HR (95% CI).
However, for comparison with CVD events, we calculated age-
adjusted CHD rates for CAC categories (0, 1–10, 11–100,
100–400, and >400), and for risk factors from 8.7 years
before cardiac CT scan (Table 2). Of the 535 women with
CAC=0, only 4 (0.77%) had incident CHD events, with a very
low age-adjusted CHD rate of 0.91 (0.17, 5.26) per 1000 PYs.
Compared with CAC=0, CHD rates were higher for any CAC
(>0). Among women with CAC 1 to 10, 2/75 (2.67%) had CHD
events (age-adjusted rate of 5.03 [1.26, 20.10]/1000 PYs),
and of the women with CAC 11 to 100, 2/176 (1.14%) had
CHD events (age-adjusted rate of 1.33 [0.19, 9.47]/
1000 PYs). Combining these 2 categories into CAC 1 to
100, 4/251 (1.59%) had CHD events, with an age-adjusted
rate (95% CI) of 2.11 (0.61, 8.12) per 1000 PYs. For CAC
>100, 9/158 (5.7%) had incident CHD, with an age-adjusted
rate (95% CI) of 7.40 (2.56, 25.09, not shown). However,
among CAC>400, 6/50 (12%) had CHD events, with an age-
adjusted rate (95% CI) of 18.22 (4.79, 74.80) per 1000 PYs.
Furthermore, although these 50 women with CAC>400 were
only 5.4% of the entire cohort, they accounted for 35% (6/17)
of the total number of CHD events. The prevalence of
CAC>400 was related to older age, smoking, hypertension,
and high cholesterol, and increased with number of risk
factors, from 3.9% of women with 0 CVD risk factors to 16% of
those with 3+ risk factors (not shown). In comparison, age-
adjusted CHD rates were modestly higher for current versus
never smokers (5.58 [2.09, 14.87] versus 2.25 [0.78, 7.46]
per 1000 PYs) and for presence versus absence of family
history of MI in first-degree relative (3.16 [1.26, 9.30] versus
1.58 [0.40, 6.32] per 1000 PYs), but were relatively similar by
other risk factors, such as hypertension yes versus no (2.82
[0.94, 8.84] versus 2.17 [0.99, 4.93] per 1000 PY, Table 2).
Age-Adjusted CVD Risk by CAC and Baseline Risk
Factor Categories
Age-adjusted CVD rates (Table 3) were also low (5.56/
1000 PY) for CAC=0, but were more than doubled with
presence of CAC starting at 11 to 100 (11.38/1000 PYs), and
increased to 47.21/1000 PY for women with CAC=400, with
a corresponding HR (95% CI)=7.97 (4.07, 15.59). Age-
adjusted CVD rates were lower for CAC=0 than with absence
of any individual risk factor except BMI<25 (only 18.3% of the
study cohort). For most risk factors, age-adjusted CVD rates
were much higher with CAC>400 than with presence of any
individual risk factor, including diabetes mellitus. In separate
age-adjusted Cox models, baseline hypertension, high choles-
terol, premature MI in first-degree relatives, and BMI (30–34.9
or >35 versus BMI <25) were also each significantly
associated with CVD, with HR >1.8 (Table 3).
Given the high rate of revascularizations, we also con-
ducted sensitivity analyses to evaluate whether associations
of CAC with CVD might be because of increased testing and
subsequent revascularizations because of knowledge of high
CAC scores. Of the 23 revascularizations that were first
events, only 8 occurred within the first 2 years after the scan.
Of these, 2 had CAC=0, 2 had scores 101 to 400, and 4 had
CAC>400. With these women excluded, results were
Figure 3. Age-adjusted mortality rates per 1000 PYs, by CAC
categories. Results are among 1020 women. CAC categories
defined as 0, 1 to 100, >100. Error bars show 95% confidence
intervals for rates. CAC indicates coronary artery calcium; CVD,
cardiovascular disease; PYs, person-years.
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essentially unchanged, although age-adjusted CVD rate/
1000 PYs was slightly lower for CAC>400: 34.21 (11.58,
101.51, not shown).
Age-Adjusted Mortality Risk by CAC and Baseline
Risk Factor Categories
Age-adjusted mortality rates (Table 4) were lowest for women
with CAC=0 (3.45/1000 PYs), were higher for CAC=1 to 10,
11 to 100, and 101 to 400 compared with CAC=0, and were
highest for women with CAC>400 (19.11/1000 PYs), base-
line high cholesterol (19.81/1000 PYs), or CVD before
cardiac scan (17.37/1000 PYs). Age-adjusted mortality rates
were also higher for hypertension versus no hypertension
(10.44 versus 5.04/1000 PYs) and waist circumference >88
versus ≤88 cm (8.47 versus 4.71/1000 PYs, Table 4). Sim-
ilarly, in separate age-adjusted Cox models, the largest HR
(95% CI): 5.67 (2.59, 12.40) was for CAC>400 (versus 0) but
prior CVD, hypertension, high cholesterol, and waist circum-
ference were also significantly associated with total mortality.
No specific cause of death uniquely contributed to the
higher incidence of total mortality among women with higher
CAC scores (not shown). Higher lung cancer deaths (n=10)
were the leading cause of death, but were distributed across
CAC scores. However, excluding women who reported current
smoking at baseline, the number of deaths was reduced from
55 to 45, but the association of CAC with total- and non-CVD
mortality persisted (not shown). For example, non-CVD deaths
were almost 5-fold higher for CAC >400 (13.3/1000 PYs, 6
deaths) compared with CAC=0 (2.8/1000 PYs, 11 deaths,
not shown).
Multivariable-Adjusted Risks of CHD, CVD, and
Mortality
The low number of CHD cases (n=17) limited power for
multivariable-adjusted Cox regression models. However, in
supplemental analyses, higher CAC category (CAC >100
versus CAC=0) was significantly associated with CHD
(HR=7.94, 95% CI, 2.40–26.34) adjusted for age and CEE-
Alone versus placebo, which was only minimally attenuated
when additionally adjusted for diabetes mellitus, smoking,
hypertension, and high cholesterol (Table S2). Results were
similar if women with CVD before scan were included,
adjusted for prior CVD, which was also not significantly
associated with CHD risk (not shown).
For incident CVD (Table 5), HR (95% CI) for CAC>100 and
CAC 1 to 100 versus CAC=0 were 4.41 (2.49–7.82) and 1.91
(1.05, 3.47), respectively, when adjusted for age and prior
randomization to CEE-Alone versus placebo, which were not
statistically significant (Model 1). In models that also included
diabetes mellitus, smoking, hypertension, and high choles-
terol (Model 2) or additionally, BMI categories (Model 3), HRs
were attenuated for these risk factors but remained signifi-
cant for CAC>100 (ref=0) in both models. Results were
similar if women with CVD before scan were included
(adjusted for prior CVD, which was not statistically significant,
not shown).
Table 1. Outcome by HT Arm and CAC Category
Event CAC
Placebo CEE-Alone
n No. of Events Age-Adjusted Rate/1000 PY (95% CI) n No. of Events Age-Adjusted Rate/1000 PYs (95% CI)
CHD* (all events) All 454 7 1.99 (0.68, 7.34) 477 10 2.72 (0.98, 7.83)
0 241 1 0.60 (0.08, 4.24) 281 3 1.30 (0.27, 6.73)
1 to 100 124 2 2.17 (0.54, 8.68) 127 2 1.98 (0.28, 14.07)
>100 89 4 5.62 (1.39, 26.76) 69 5 9.69 (2.31, 48.02)
CVD* (first CVD event) All 454 28 8.08 (4.37, 15.21) 477 41 11.08 (6.53, 18.85)
0 241 9 4.90 (1.63, 15.19) 281 14 6.11 (2.49, 15.28)
1 to 100 124 8 9.12 (3.03, 29.61) 127 12 13.07 (5.19, 34.39)
>100 89 11 15.78 (5.90, 50.20) 69 15 34.18 (14.38, 82.39)
Death† All 503 33 8.38 (4.76, 15.03) 517 22 5.43 (2.71, 11.06)
0 256 9 4.70 (1.64, 14.30) 294 6 2.53 (0.82, 7.86)
1 to 100 135 11 9.91 (3.57, 28.57) 138 9 8.74 (3.06, 26.56)
>100 112 13 14.16 (5.67, 40.21) 85 7 11.07 (3.05, 40.77)
CAC indicates coronary artery calcium; CEE, conjugated equine estrogen; CHD, coronary heart disease; CVD, cardiovascular disease; HF, heart failure; HT, hormone therapy; PY, person-
years.
*n=931, excluding surgical stent (n=10), no follow-up (n=44), and prior CVD (n=89).
†n=1020, excluding surgical stent (n=10), no follow-up (n=44).
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Finally, for total mortality (Table 5), HR (95% CI) were 3.06
(1.53, 6.12) for CAC>100 and 2.56 (1.35, 5.16) for CAC 1 to
100 (ref=CAC=0), adjusted for prior CVD (HR: 2.43, 95% CI,
1.26, 4.70), age and randomization to CEE-Alone versus
placebo (Model 1). CAC>100 (versus 0) remained significantly
associated with total mortality when further adjusted for
diabetes mellitus, smoking, hypertension, high cholesterol,
and prior CVD (Model 2), or additionally for BMI categories
(Model 3). However, in Models 2 and 3, high cholesterol was
the only covariate that remained significantly associated with
total mortality. If restricted to women without CVD before the
scan, results were similar except for a stronger association of
smoking (HR: 2.24, 95% CI, 1.05, 4.79) with total mortality
(not shown).
Sensitivity Analyses
We evaluated effects of recategorizing current smoking (yes/
no) to examine high levels of current smoking exposure (ie, 1
to 14 cigarettes/d [n=58] and >15 cigarettes/d [n=48]). Age-
adjusted CVD rates for current smoking: no (never and former
smokers, 9.28/1000 PYs) and for yes (1–14 cigarettes/d,
7.23/1000 PY) were similar to those in Table 3 for never
smokers (9.93/1000 PYs) and were also approximately twice
as high as for CAC=0 (5.56/1000 PYs). However, for current
smokers with 15 or more cigarettes/d, the age-adjusted CVD
rate was 23.78/1000 PY, which was higher than CAC
categories except for CAC>400 (47.21/1000 PYs), and had
an age-adjusted HR (95% CI)=2.35 (1.07, 5.15). We also reran
multivariable models using this smoking categorization, and
also replacing hypertension (yes/no) with systolic blood
pressure categories (<118, 118–130, and >130 mm Hg,
Table S3). The multivariable-adjusted HRs for CAC>100 in
Models 2 and 3 are almost identical to those in our primary
multivariable models (Table 5). However, for current smokers
of 15+ cigarettes per day, adjusting for CAC and other risk
factors has little effect on HRs (2.35 to 2.27 or 2.32),
although they miss statistical significance.
Finally, we also performed sensitivity analyses including
the entire WHI-CACS with no exclusions, and including as
incident event those that occurred between WHI baseline and
CT scan, as well as from scan to end of follow-up. The results
were very similar to our primary results (Table S4). For
example, for both MI and for CVD, rates were higher with
higher CAC category but similar for women previously
randomized to CEE-alone compared with placebo. As in the
primary results, age-adjusted stroke rates were only minimally
higher for CAC>100 versus 0 (2.85 versus 1.43 per 1000
PYs), although similar for CEE-alone versus placebo
(Table S4).
Discussion
This long-term follow-up of the WHI-CACS is the only study
relating CAC to subsequent risk of CHD, CVD, and death
among a subset of prior participants in a randomized clinical
trial of estrogen alone versus placebo. The WHI-CACS has
Table 2. Age-Adjusted CHD Rates/1000 PY by CAC and
Baseline Characteristics, n=931*
Characteristic N No. CHD
Age-Adjusted CHD
Rate/1000 PY (95% CI)
CAC
0 522 4 0.91 (0.17, 5.26)
1 to 10 75 2 5.03 (1.26, 20.10)
11 to 100 176 2 1.33 (0.19, 9.47)
101 to 400 108 3 2.77 (0.89, 8.59)
>400 50 6 18.22 (4.79, 74.80)
Age group, y†
50 to 54 375 4 0.86 (0.32, 2.29)
55 to 59 556 13 2.89 (1.39, 6.33)
Smoking
Never 455 8 2.25 (0.78, 7.46)
Past 364 5 1.70 (0.39, 7.92)
Current 106 4 5.58 (2.09, 14.87)
Hypertension
No 661 11 2.17 (0.99, 4.93)
Yes 267 6 2.82 (0.94, 8.84)
High cholesterol
No 728 12 2.15 (0.87, 5.64)
Yes 70 2 3.25 (0.81, 13.00)
Diabetes mellitus
No 884 16 2.34 (1.06, 5.38)
Yes 46 1 3.00 (0.42, 21.32)
MI in first-degree relative
No 478 6 1.58 (0.40, 6.32)
Yes 406 10 3.16 (1.26, 9.30)
Body mass index, kg/m2
<25 170 4 3.47 (0.98, 13.86)
25.1 to 29.9 315 4 1.61 (0.31, 8.99)
30 to 34.9 238 6 3.23 (0.98, 13.06)
≥35 203 3 1.87 (0.39, 9.76)
Waist circumference, cm
≤88 407 8 2.71 (1.09, 7.15)
>88 522 9 2.24 (0.79, 6.92)
CAC indicates coronary artery calcium; CHD, coronary heart disease; MI, myocardial
infarction; PY, person-years.
*Excluding no follow-up (n=44) or CVD before scan (n=89).
†All results except age are age-adjusted.
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previously reported that among these women aged 50 to 59
years at baseline, randomization to CEE-alone versus placebo
was associated with lower CAC scores measured 8.7 years
later, at mean age 64.4 years, independent of baseline CVD
risk factors.5 The current report shows that among these
relatively young postmenopausal women, age-adjusted rates
of CHD, CVD, and mortality were very low among the 54% with
CAC=0, and >2-fold higher for those with any CAC. CAC>100
(versus 0) was associated with CHD (HR=7.88), CVD
(HR=4.06), and total mortality (HR=2.70), adjusted for prior
randomization to CEE-alone versus placebo and baseline CVD
risk factors. Furthermore, associations of CAC with post-trial
CVD outcomes and mortality were not modified by prior
randomization to CEE-alone versus placebo, and associations
of baseline CVD risk factors with incident CVD and total
mortality were attenuated when adjusted for CAC.
Our study results must be interpreted within the context of
this unique study. Previous reports showed that among
women aged 50 to 59 years at baseline in the overall WHI
E-Alone trial, randomization to E-Alone versus placebo was
associated with lower risk of MI, CHD, and mortality during
the trial and in long-term follow-up.3 Among women aged 50
to 59 years at baseline in the WHI E-Alone Trial, the WHI-
CACS showed that randomization to E-Alone versus placebo
resulted in lower odds of CAC measured 8.7 years after
baseline, independent of CVD risk factors also associated with
subsequent CAC.5 The long incubation period for CAC has
been demonstrated by longitudinal studies, showing stronger
Table 3. Age-Adjusted CVD* Incidence Rates/1000 PY by CAC and Baseline Characteristics, n=931†
Characteristic N No. CVD
Age-Adjusted CVD
Rate/1000 PY
Age-Adjusted HR
(95% CI)‡
CAC 0 522 23 5.56 (2.74, 11.31) 1.00
1 to 10 75 5 9.63 (2.28, 42.26) 1.53 (0.58, 4.03)
11 to 100 176 15 11.38 (4.90, 27.39) 2.02 (1.05, 3.88)§
101 to 400 108 12 14.93 (5.55, 42.36) 2.69 (1.32, 5.45)§
>400 50 14 47.21 (19.20, 118.28) 7.97 (4.07, 15.59)§
Age group, yk 50 to 54 375 23 8.12 (4.23, 16.27) 1.00
55 to 59 556 46 10.92 (7.25, 16.49) 1.56 (0.58, 4.21)
Current smoking Never 455 35 9.93 (5.65, 17.54) 1.00
Past 364 24 8.50 (4.25, 17.01) 0.86 (0.51, 1.45)
Current 106 10 13.74 (5.29, 40.17) 1.34 (0.66, 2.71)
Hypertension No 661 40 7.86 (4.67, 13.34) 1.00
Yes 267 29 14.55 (7.74, 27.32) 1.87 (1.16, 3.01)§
High cholesterol No 728 46 8.19 (5.01, 13.47) 1.00
Yes 70 9 17.79 (5.88, 57.35) 2.05 (1.00, 4.21)§
Diabetes mellitus No 884 63 9.29 (6.08, 14.21) 1.00
Yes 46 6 18.19 (4.94, 72.31) 1.88 (0.82, 4.35)
MI in first-degree relative No 478 25 6.80 (3.47, 13.36) 1.00
Yes 406 40 12.82 (7.53, 21.92) 1.90 (1.15, 3.13)§
Body mass index, kg/m2 <25 170 6 4.89 (1.35, 19.02) 1.00
25 to 29.9 315 22 9.02 (4.37, 18.68) 1.96 (0.79, 4.83)
30 to 34.9 238 23 12.74 (6.47, 25.58) 2.72 (1.11, 6.69)§
≥35 203 18 11.63 (5.22, 25.99) 2.60 (1.03, 6.56)§
Waist circumference, cm ≤88 407 23 7.50 (3.77, 15.06) 1.00
>88 522 46 11.51 (6.99, 18.96) 1.57 (0.95, 2.59)
CAC indicates coronary artery calcium; CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; PY, person-years.
*n=69 first events.
†Excluding no follow-up (n=44) or prior CVD (n=89).
‡HR (95% CI) from separate Cox Proportional Hazards Regression models, adjusted for age.
§Statistically significant results.
kNot adjusted for age.
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associations with risk factors measured 11 to 20 years before
CAC scan than to concurrently measured risk factors.11–13 As
hypothesized, the association of higher CAC with subsequent
CVD events and mortality was not modified by prior random-
ization to E-Alone versus placebo and not attenuated by
randomized treatment or baseline CVD risk factors.
Table 4. Age-Adjusted Total Mortality Rates/1000 PY by CAC and Baseline Characteristics, n=1020*
Characteristic N No. Deaths
Age-Adjusted Death
Rate/1000 PY (95% CI)
Age-Adjusted
HR (95% CI)†
CAC
0 550 15 3.45 (1.53, 8.22) 1.00
1 to 10 80 7 12.57 (4.04, 43.00) 3.24 (1.32, 7.94)‡
11 to 100 193 13 8.16 (3.22, 21.70) 2.44 (1.16, 5.14)‡
101 to 400 125 9 10.31 (4.03, 26.42) 2.57 (1.12, 5.91)‡
>400 72 11 19.11 (8.23, 44.99) 5.67 (2.59, 12.40)‡
Prior CVD
No 931 43 5.85 (3.54, 9.74) 1.00
Yes 89 12 17.37 (6.60, 51.46) 3.02 (1.59, 5.77)‡
Age group, y§
50 to 54 401 17 5.62 (2.65, 12.50) 1.00
55 to 59 619 38 7.53 (4.86, 11.87) 0.54 (0.17, 1.70)
Smoking
Never 496 25 6.26 (3.21, 12.30) 1.00
Past 401 20 6.37 (3.15, 13.46) 1.01 (0.56, 1.82)
Current 117 10 11.42 (4.21, 33.63) 1.83 (0.88, 3.82)
Hypertension
No 698 28 5.04 (2.76, 9.47) 1.00
Yes 319 26 10.44 (5.48, 20.25) 2.08 (1.22, 3.56)‡
High cholesterol
No 786 35 5.71 (3.32, 10.02) 1.00
Yes 83 13 19.81 (7.78, 53.94) 3.37 (1.77, 6.39)‡
Diabetes mellitus
No 957 52 6.90 (4.38, 10.96) 1.00
Yes 62 3 6.01 (1.26, 30.99) 0.89 (0.28, 2.84)
MI in first-degree relative
No 505 24 6.22 (3.37, 12.17) 1.00
Yes 465 27 7.22 (3.79, 13.91) 1.17 (0.67, 2.03)
Body mass index, kg/m2
<25 179 8 5.57 (1.68, 18.70) 1.00
25.1 to 29.9 344 16 5.74 (2.77, 13.57) 0.99 (0.42, 2.46)
30 to 34.9 269 13 5.98 (2.42, 15.37) 1.02 (0.42, 2.46)
≥35 223 18 10.64 (4.99, 23.33) 1.87 (0.81, 4.30)
Waist circumference, cm
≤88 436 16 4.71 (2.08, 10.90) 1.00
>88 581 39 8.47 (5.00, 14.51) 1.80 (1.01, 3.22)‡
CAC indicates coronary artery calcium; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; PY, person-years.
*Excluding stents (n=10) or no follow-up (n=44).
†HR (95% CI) from separate Cox Proportional Hazards Regression models, adjusted for age.
‡Statistically significant results.
§Not adjusted for age.
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Furthermore, associations of baseline CVD risk factors with
post-trial events and mortality were attenuated in multivari-
able-adjusted models including CAC.
In this study of postmenopausal women, CVD risk was
especially high for the 5% of women with CAC >400; these
women accounted for 35% of CHD events and 61% of CVD
events, and they had age-adjusted rates/1000 PY of 16.74
(CHD), 47.21 (CVD), and 19.11 (total mortality). However,
women with CAC=0 (more than half the cohort) had very low
age-adjusted rates of CHD, CVD, and mortality over 8 years
of follow-up, lower than for absence of most other baseline
risk factors. This agrees with a prior report of low mortality
rates for older adults with CAC=0, even for those aged
≥75 years.14 Compared with the >50% of women with
CAC=0, rates were doubled for women with any CAC, starting
at CAC 11 to 100 for CVD and CAC 1 to 10 for mortality. In
absolute risk, the age-adjusted CVD rate/1000 PYs for CAC
11 to 100 (11.38) is similar to family history of MI in first-
degree relatives (12.82) and is intermediate between former
smokers (8.50) and current smokers (13.74). Our results
agree with prior reports showing that presence of any CAC
(>0) is associated with increased CVD and mortality among
women with a broader age range,14,15 as well younger adults
over 10 to 15 years of follow-up.16 Among younger adults in
the CARDIA (Coronary Artery Risk Development in Young
Adults) study, CVD risk was higher with any CAC starting as
low as CAC=1 to 19.16
Interestingly, total mortality was positively related to the
extent of CAC, and to high cholesterol, despite the very few
deaths caused by CVD. High cholesterol was associated with
total mortality before and after adjustment for CAC, even
when women with CVD before scan were excluded. However,
since high cholesterol was defined based on self-report of
prior diagnosis or treatment, it may be a marker for poorer
health (ie, women who are in the healthcare system for other
reasons). Measured lipid levels, if available, might have had
stronger or weaker associations with outcomes. The associ-
ation of CAC with total mortality persisted even if excluding
CVD before the scans or current smokers at baseline. The
MESA (Multi-Ethnic Study of Atherosclerosis) study has also
reported an association of higher CAC with higher noncar-
diovascular morbidity and mortality.17 The association of CAC
with higher non-CVD mortality suggests that CAC represents
not only the cumulative exposure to CVD risk factors but also
other aspects of the aging process that may contribute both
to high CAC scores and morbidity and mortality from other
causes.18,19 Furthermore, a high CAC score indicates a
systemic burden of subclinical cardiovascular disease that
may increase the likelihood of death following diagnosis or
treatment for noncardiovascular diseases. Additional studies
are needed to identify potential nonatherosclerotic factors
that contribute to differences in CAC between populations,
and to the association between CAC and non-CVD morbidity
and mortality.
The results of this studymust be carefully interpreted in light
of study strengths and limitations. As noted, this is the only
follow-up of CAC for events nested within a randomized trial of
Table 5. Multivariable-Adjusted HR (95% CI) for CVD and
Total Mortality Risk by CAC Categories
Predictors
CVD
HR (95% CI)
n=931*
Total Mortality
HR (95% CI)
n=1020†
Model 1‡
CAC=0 1.0 (ref) 1.0 (ref)
CAC 1 to 100 1.91 (1.05, 3.47)§ 2.56 (1.31, 5.00)§
CAC >100 4.41 (2.49, 7.82)§ 3.06 (1.53, 6.12)§
Age, y 1.01 (0.93, 1.10) 1.08 (0.97, 1.19)
Prior CVD (yes vs no) n/a 2.43 (1.26, 4.70)§
Model 2‡
CAC=0 1.0 (ref) 1.0 (ref)
CAC 1 to 100 (ref=0) 1.65 (0.83, 3.28) 1.97 (0.93, 4.18)
CAC >100 (ref=0) 4.06 (2.11, 7.80)§ 2.70 (1.26, 5.79)§
Age, y 1.02 (0.92, 1.12) 1.11 (0.99, 1.25)
Diabetes mellitus (yes vs no) 1.72 (0.72, 4.12) 0.65 (0.20, 2.15)
Current smoking (yes vs no) 1.09 (0.51, 2.34) 1.81 (0.89, 3.69)
Hypertension 1.22 (0.70, 2.15) 1.70 (0.92, 3.15)
High cholesterol (yes vs no) 1.63 (0.79, 3.36) 2.61 (1.34, 5.06)§
Prior CVD (yes vs no) n/a 1.54 (0.69, 3.41)
Model 3‡
CAC=0 1.0 (ref) 1.0 (ref)
CAC 1 to 100 (ref=0) 1.56 (0.78, 3.12) 1.90 (0.90, 4.07)
CAC >100 (ref=0) 3.98 (2.07, 7.67)§ 2.66 (1.24, 5.74)§
Age, y 1.02 (0.92, 1.12) 1.12 (1.00, 1.26)
Diabetes mellitus (yes vs no) 1.55 (0.64, 3.75) 0.64 (0.19, 2.13)
Current smoking (yes vs no) 1.13 (0.53, 2.42) 1.90 (0.92, 3.93)
Hypertension 1.16 (0.65, 2.06) 1.55 (0.82, 2.96)
High cholesterol (yes vs no) 1.68 (0.81, 3.47) 2.62 (1.35, 5.09)§
BMI <25 1.0 (ref) 1.0 (ref)
BMI 25 to 29.9 1.47 (0.57, 3.75) 0.81 (0.33, 1.95)
BMI 30 to 34.9 2.01 (0.79, 5.13) 0.62 (0.23, 1.63)
BMI ≥35 1.48 (0.55, 4.00) 1.32 (0.53, 3.26)
Prior CVD (yes vs no) n/a 1.67 (0.75, 3.72)
BMI indicates body mass index; CAC, coronary artery calcium; CEE, conjugated equine
estrogen; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; n/a, not
applicable.
*Excludes women with CVD at baseline or before CAC scan, or no follow-up, n=931.
†Excludes with no follow-up, n=1020.
‡Each model is adjusted for CEE vs placebo (not shown) as well as the predictors
reported for that model.
§Statistically significant results.
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CEE-Alone versus placebo. However, the WHI E-Alone Trial
included only hysterectomized women, and the WHI-CACS
included only a subset of former WHI E-Alone trial participants.
This study assesses only postscan events, occurring 1.3 to
9 years after intervention had stopped. Furthermore, for CHD
and CVD analyses, the current report excludes women with
CVD before scan, which excludes those with events between
baseline and scan (ie, during the intervention). The power to
evaluate associations with incident events, especially when
stratified by prior randomization to CEE-Alone versus placebo,
is limited by the low rates of CHD, CVD, and CVD mortality.
These low event rates are related to the very low prevalence of
CAC (ie, 54% of the women had CAC=0 and 62% had CAC <10),
consistent with other studies showing much lower prevalence
of coronary calcification in women than men, and very low
incidence of CHD and CVD in both men and women with low
CAC scores.7,20 Finally, while presence and severity of CAC is
strongly associated with the overall atherosclerotic plaque
burden, it does not quantify noncalcified plaque, and may also
represent inflammation or other determinants of tissue calci-
fication.21–23 In spite of this, our results agree with other
studies that have shown that for both men and women, CAC=0
is associated with extremely low risk of CHD over the next 10 to
15 years, and there is a consistent linear relationship between
the amount of CAC and the risk of CHD and CVD.16 Additional
studies of lower risk populations are needed to validate our
findings that CHD and CVD risk are higher with any versus no
CAC, even among those with low CAC scores.
In this study, as in the total WHI follow-up study1,3 the
most common CVD event was coronary revascularization,
which may have introduced bias if high CAC scores prompted
revascularization among some asymptomatic women. How-
ever, the majority of first event revascularizations occurred
more than 2 years after cardiac CT scan, and associations
with CAC were similar when revascularizations within 2 years
of scan were excluded. Also, since WHI did not include
nonhospitalized angina pectoris as a primary end point, some
women with revascularization as their first event likely had
angina symptoms before revascularization. Finally, associa-
tions of CAC with CVD were very similar to associations with
CHD (MI and CHD death), supporting the conclusion that the
association of CAC with CVD in this study is not biased by the
possibility of revascularizations prompted by knowledge of
high CAC scores.
In conclusion, among postmenopausal women, those with
any CAC (>0) have a higher risk of CVD and mortality
compared with women with no CAC. Associations were
minimally attenuated when adjusted for baseline CVD risk
factors previously shown to predict CAC in this study cohort.
Although prior randomized treatment was significantly asso-
ciated with CAC levels measured 8.7 years after baseline,
prior randomization did not modify associations of CAC with
outcomes. This agrees with the proposition that CAC is the
result of cumulative prior exposures including measured and
unmeasured risk factors, host susceptibility, and duration of
exposures, and therefore outperforms single risk factor
measurements. Only 19.3% of women had high CAC (>100),
but they were at significantly higher risk for CVD outcomes
and mortality. At the other extreme, the 50% of women with
zero CAC have very low risk of CVD. However, over time,
some of the postmenopausal women with CAC=0 will develop
calcification, as previously shown among healthy post-
menopausal women.24 These results suggest that prevention
of CAC among young and midlife women may delay morbidity
and mortality among postmenopausal women. Whether CAC
screening should be recommended for postmenopausal
women to identify both very high risk and very low risk
women remains an important unanswered question of con-
siderable public health relevance in an aging population.
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Florida, Gainesville/Jacksonville, FL) Marian Limacher;
(University of Iowa, Iowa City/Davenport, IA) Jennifer Robin-
son; (University of Pittsburgh, Pittsburgh, PA) Lewis Kuller;
(Wake Forest University School of Medicine, Winston-Salem,
NC) Sally Shumaker; (University of Nevada, Reno, NV) Robert
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SUPPLEMENTAL MATERIAL 
  
Table S1. Participant Characteristics, Overall,* and for CEE-Alone vs. Placebo 
   
Total 
(n=1020) 
Placebo 
(n=503) 
CEE-Alone 
(n=517)   
  Mean SD Mean SD Mean SD p-value 
Age, years  55.13 2.87 55.14 2.94 55.11 2.80 0.88 
Age at scan 64.38 2.89 64.38 2.92 64.39 2.85 0.94 
Body Mass Index, kg/m2 30.56 6.04 30.58 6.28 30.54 5.79 0.91 
Waist Circumference, cm 91.65 14.33 91.52 14.33 91.77 14.34 0.79 
SBP, mmHg 124.54 15.70 125.20 16.60 123.90 14.77 0.18 
DBP, mmHg 77.79 8.86 78.06 8.81 77.53 8.91 0.34 
log METs 1.76 1.21 1.79 1.23 1.73 1.19 0.45 
CAC score  98.22 294.98 120.92 349.90 76.12 227.44 0.01 
Categorical   n % n % n % p-value 
Diabetes no 957 93.92 470 93.63 487 94.20   
 
yes 62 6.08 32 6.37 30 5.80 0.70 
Smoking never 496 48.92 248 49.60 248 48.25 
 
 
past 401 39.55 198 39.60 203 39.49 
 
 
current 117 11.54 54 10.80 63 12.26 0.76 
Hypertension no 698 68.63 348 69.32 350 67.96 
 
 
yes 319 31.37 154 30.68 165 32.04 0.64 
High cholesterol  no 786 90.45 386 90.61 400 90.29 
 
 
yes 83 9.55 40 9.39 43 9.71 0.87 
MI in 1st degree 
relative 
no 505 52.06 251 51.75 254 52.37 
 yes 465 47.94 234 48.25 231 47.63 0.85 
CVD prior to scan no 931 91.27 454 90.26 477 92.26 
 
 
yes 89 8.73 49 9.74 40 7.74 0.26 
CAC score 0 550 53.92 256 50.89 294 56.87 
 
 
1-100 273 26.76 135 26.84 138 26.69 
  >100 197 19.31 112 22.27 85 16.44 0.05 
Table S1. Cont’d 
CAC indicates coronary artery calcium; CEE, conjugated equine estrogen; CVD, cardiovascular disease; DBP, 
diastolic blood pressure; METs, metabolic equivalents; MI, myocardial infarction; and SBP, systolic blood pressure 
* excludes n=10 with surgical stent and n=44 without follow up data 
p values from t-test, Wilcoxon rank sum test or chi square tests compare CEE-Alone vs. placebo.   
 
 
 
 
  
Table S2. Multivariable-adjusted HR(95%CI) for CHD by CAC Categories 
  
  
  
CHD* 
HR(95%CI) 
Model 1†  CAC = 0 1.0 (ref) 
  CAC 1-100 (ref=0) 2.13 (0.53, 8.54) 
  CAC > 100 (ref=0 7.94 (2.40, 26.34) 
  Age 1.07 (0.89, 1.28) 
Model 2†  CAC = 0 1.0 (ref) 
  CAC 1-100 (ref=0) 2.67 (0.59, 12.11) 
  CAC > 100 (ref=0) 7.88 (1.94, 31.98) 
  Age 1.15 (0.92, 1.44) 
  
Diabetes 1.17 (0.14, 9.54) 
  
Smoking 0.71 (0.21, 2.38) 
  
Hypertension 1.32 (0.29, 5.98) 
  
High cholesterol 2.42 (0.74, 7.86) 
Model 3†  CAC = 0 1.0 (ref) 
  CAC 1-100 (ref=0) 2.64 (0.57, 12.22) 
  CAC > 100 (ref=0) 8.69 (2.11, 35.86) 
  Age 1.15 (0.92, 1.43) 
  
Diabetes 1.04 (0.12, 9.23) 
  
Smoking 2.40 (0.72, 8.05) 
  
Hypertension 0.77 (0.21, 2.78) 
  
High cholesterol 1.44 (0.32, 6.70) 
  
Hot flashes 0.88 (0.23, 3.36) 
  
BMI 25-29.9 0.40 (0.09, 1.80) 
  
BMI 30-34.9 1.06 (0.28, 4.08) 
  
BMI ≥35 0.19 (0.02, 1.79) 
BMI indicates body mass index; CAC, coronary artery calcium; and CHD, coronary heart 
disease. *Excludes women with CVD at baseline or prior to CAC scan, or no follow-up 
n=931. † Covariates include CEE-alone vs. placebo and the variables reported for each 
model. Statistically significant results are bolded.    
Table S3. Multivariable-adjusted HR(95%CI) for CVD* with Recategorized Current 
Smoking and Systolic Blood Pressure 
 
  
HR (95% CI) 
Model 1† CAC 1-100 (ref=0) 1.91 (1.05, 3.47) 
 
CAC >100 (ref=0) 4.41 (2.49, 7.82) 
 
Age , years 1.01 (0.93, 1.10) 
Model 2† CAC 1-100 (ref=0) 1.58 (0.79, 3.14) 
 
CAC >100 (ref=0) 4.05 (2.12, 7.75) 
 
Age , years 1.02 (0.93, 1.13) 
 
Diabetes (ref=no) 1.84 (0.78, 4.36) 
 
Current smoker: # cigarettes 1-14 (ref=no current 
smoking) 0.48 (0.12, 2.01) 
 
Current smoker: # cigarettes 15+ (ref=no current 
smoking) 2.27 (0.94, 5.49) 
 
SBP 118-130 mmHg (ref =SBP<118) 1.25 (0.63, 2.46) 
 
SBP >130 mmHg (ref =SBP<118) 1.44 (0.74, 2.81) 
  High cholesterol (ref=no) 1.76 (0.86, 3.64) 
Model 3† CAC 1-100 (ref=0) 1.51 (0.75, 3.01) 
 
CAC >100 (ref=0) 3.96 (2.07, 7.57) 
 
Age , years 1.03 (0.93, 1.13) 
 
Diabetes (ref=no) 1.67 (0.70, 4.00) 
 
Current smoker: # cigarettes 1-14 (ref=no current 
smoking) 0.50 (0.12, 2.06) 
 
Current smoker: # cigarettes 15+ (ref=no current 
smoking) 2.32 (0.94, 5.68) 
 
SBP 118-130 mmHg (ref =SBP<118) 1.19 (0.60, 2.35) 
 
SBP >130 mmHg (ref =SBP<118) 1.35 (0.69, 2.63) 
 
High cholesterol (ref=no) 1.78 (0.87, 3.68) 
 
BMI 25-29.9 (ref= BMI<25) 1.38 (0.54, 3.54) 
 
BMI 30-34.9 (ref= BMI<25) 1.94 (0.76, 4.93) 
  BMI ≥35 (ref= BMI<25) 1.50 (0.56, 4.05) 
BMI indicates body mass index; CAC, coronary artery calcium; CEE, conjugated equine 
estrogen; CVD, cardiovascular disease; and PY, person-years 
*Excludes women with CVD at baseline or prior to CAC scan, or no follow-up n=931.  
† Each model is adjusted for CEE vs. placebo (not shown) as well as the predictors reported for 
that model. Statistically significant results are bolded.   
 
 
 
Table S4. All Incident CVD Outcomes from WHI Baseline by CAC Categories for E-Alone, Placebo and Total (combined), n=1074* 
 
E-Alone Control E-Alone Intervention All (E-Alone + Placebo) 
 
Total Events 
Age-adjusted rate/1000 PY 
Total Events Age-adjusted rate/1000 PY 
 
Total Events 
Age-adjusted rate/1000 PY 
Event CAC n n % n n % n n % 
MI all 529 19 3.59 2.09 (0.99,4.61) 545 17 3.12 1.80 (0.79,4.16) 1074 36 3.35 1.93 (1.10,3.43) 
 
0 267 4 1.50 0.69 (0.10,4.91) 301 4 1.33 0.75 (0.20,3.19) 568 8 1.41 0.69 (0.21,2.65) 
 
1-
100 
142 5 3.52 2.01 (0.60,6.86) 152 3 1.97 0.79 (0.11,5.58) 294 8 2.72 1.40 (0.50,3.96) 
  >100 120 10 8.33 4.94 (1.79,16.51) 92 10 10.87 7.13 (2.47,21.30) 212 20 9.43 5.94 (2.81,13.15) 
Stroke all 529 15 2.84 1.74 (0.75,4.16) 545 14 2.57 1.52 (0.63,3.79) 1074 29 2.70 1.64 (0.88,3.07) 
 
0 267 5 1.87 1.22 (0.32,5.52) 301 8 2.66 1.57 (0.53,5.30) 568 13 2.29 1.43 (0.59,3.60) 
 
1-
100 
142 4 2.82 1.77 (0.44,7.06) 152 2 1.32 0.79 (0.11,5.61) 294 6 2.04 1.21 (0.32,5.09) 
  >100 120 6 5.00 2.61 (0.91,9.28) 92 4 4.35 3.05 (0.63,16.06) 212 10 4.72 2.85 (0.99,8.94) 
CVD all 529 70 13.23 8.04 (5.36,12.14) 545 70 12.84 7.41 (4.87,11.30) 1074 140 13.04 7.73 (5.77,10.37) 
 
0 267 18 6.74 4.21 (1.91,9.42) 301 20 6.64 3.77 (1.73,8.21) 568 38 6.69 3.94 (2.25,6.90) 
 
1-
100 
142 16 11.27 7.01 (3.03,16.61) 152 21 13.82 7.56 (3.48,16.97) 294 37 12.59 7.25 (4.08,13.05) 
  >100 120 36 30.00 19.21 (10.49,35.92) 92 29 31.52 22.08 (11.57,42.30) 212 65 30.66 20.63 (13.24,32.31) 
BMI indicates body mass index; CAC, coronary artery calcium; CEE, conjugated equine estrogen; CHD, coronary heart disease; CVD, cardiovascular disease; HF, heart failure; HT, 
hormone therapy; TIA, transient ischemic attack; PAD, peripheral artery disease; and PY, person-years 
* no exclusions; follow up time: from study entry to event or end of follow up.  
